Market cap
$18 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
22.9
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -- | -- | -- | -- | -- |
| EBIT | -- | -- | 16.75 | -3.80 | -17.86 |
| Net Profit | 81.07 | 33.37 | 6.10 | -7.81 | -29.51 |
| EPS | 86.40 | 83.35 | 24.38 | -39.11 | 10.76 |
| Book Value | -- | -- | 134.41 | -2.28 | -- |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Dec-25 | Dec-24 |
| EBIT-Margin
| -- | -- | -- | -- | -- |
| Net Margin
| -- | -- | -- | -- | -- |
| Return on equity
| -172.47 | -95.17 | -- | -203.63 | -182.35 |
| Return on Capital
| -91.99 | 26.51 | -- | -106.54 | -102.16 |
| Return on Assets
| -80.06 | -71.79 | -188.44 | -89.91 | -89.90 |
| Debt to Equity (x)
| -- | -- | 0.00 | 1.22 | 0.80 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Tempest Therapeutics (TPST)
|
--
|
-106.54
|
-102.16
|
-67.29
|
-75.27
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
--
--
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Tempest Therapeutics (TPST)
|
--
|
-203.63
|
-182.35
|
-131.42
|
-131.70
|
|
Peer Median
|
-40.40
|
--
|
--
|
--
|
--
|
ROA
-188.44
Lower than Peers by 157.46
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Tempest Therapeutics (TPST)
|
-188.44
|
-89.91
|
-89.90
|
-60.38
|
-59.85
|
|
Peer Median
|
-30.98
|
--
|
--
|
--
|
--
|
EBIT Margin
--
--
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Tempest Therapeutics (TPST)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
-83.62
|
--
|
--
|
--
|
--
|
Net Margin
--
--
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Tempest Therapeutics (TPST)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
-92.67
|
--
|
--
|
--
|
--
|
Revenue Growth
--
--
Year on year growth in net sales
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Tempest Therapeutics (TPST)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
53.95
|
--
|
--
|
--
|
--
|
EBIT Growth
16.75
Higher than Peers by 17.55
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Tempest Therapeutics (TPST)
|
16.75
|
35.71
|
-44.52
|
17.74
|
-26.17
|
|
Peer Median
|
-0.80
|
--
|
--
|
--
|
--
|
Net Profit Growth
6.10
Higher than Peers by 13.40
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Tempest Therapeutics (TPST)
|
6.10
|
37.24
|
-41.88
|
17.41
|
-26.17
|
|
Peer Median
|
-7.30
|
--
|
--
|
--
|
--
|
EPS Growth
24.38
Higher than Peers by 9.73
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Tempest Therapeutics (TPST)
|
24.38
|
-3.22
|
-0.09
|
0.60
|
0.19
|
|
Peer Median
|
14.65
|
--
|
--
|
--
|
--
|
Book Value Growth
-102.78
Lower than Peers by 92.61
Year on year growth in book value per share
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Tempest Therapeutics (TPST)
|
-102.78
|
--
|
--
|
--
|
--
|
|
Peer Median
|
-10.18
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
--
--
Total debt / Net worth
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Tempest Therapeutics (TPST)
|
--
|
1.22
|
0.80
|
0.77
|
1.22
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
-1.18
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Tempest Therapeutics (TPST)
|
-1.18
|
0.18
|
0.38
|
0.20
|
0.08
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
0.38
Lower than Peers by 5.43
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Tempest Therapeutics (TPST)
|
0.38
|
2.50
|
2.21
|
4.29
|
4.53
|
|
Peer Median
|
5.81
|
--
|
--
|
--
|
--
|
Quick Ratio
0.38
Lower than Peers by 5.31
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Tempest Therapeutics (TPST)
|
0.38
|
--
|
--
|
--
|
--
|
|
Peer Median
|
5.70
|
--
|
--
|
--
|
--
|
Interest Coverage
-206.55
Lower than Peers by 204.46
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Tempest Therapeutics (TPST)
|
-206.55
|
-125.87
|
-30.80
|
-19.35
|
-21.07
|
|
Peer Median
|
-2.09
|
--
|
--
|
--
|
--
|
Operating Efficiency
Debtors to sales
--
--
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Tempest Therapeutics (TPST)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
19.14
|
--
|
--
|
--
|
--
|
Asset Turnover
--
--
Sales / Average Total Assets
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Tempest Therapeutics (TPST)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
0.06
|
--
|
--
|
--
|
--
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Tempest Therapeutics (TPST)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Tempest Therapeutics (TPST)
|
--
|
--
|
--
|
--
|
318.34
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Tempest Therapeutics (TPST)
|
--
|
--
|
1,546.91
|
936.13
|
211.32
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Tempest Therapeutics (TPST)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
--
--
Current share price divided by earning per share in the last twelve months
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Tempest Therapeutics (TPST)
|
--
|
-0.45
|
-0.56
|
-3.21
|
-0.34
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Price / Book Value
22.94
Higher than Peers by 17.76
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Tempest Therapeutics (TPST)
|
22.94
|
1.79
|
1.22
|
3.54
|
0.67
|
|
Peer Median
|
5.18
|
--
|
--
|
--
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Tempest Therapeutics (TPST)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EV/EBITDA
0.31
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Tempest Therapeutics (TPST)
|
0.31
|
-0.48
|
-0.21
|
-2.75
|
-0.09
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Market Cap
18
Lower than Peers by 129
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Tempest Therapeutics (TPST)
|
18
|
--
|
--
|
--
|
--
|
|
Peer Median
|
146
|
--
|
--
|
--
|
--
|